Stock AMWAY AMWAY (MALAYSIA) HOLDINGS
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Amway (Malaysia) Holdings

Equities

AMWAY

MYL6351OO000

End-of-day quote BURSA MALAYSIA
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
7.23 MYR +0.14% Intraday chart for Amway (Malaysia) Holdings -0.96% +22.96%
Apr. 23 Amway Holdings Berhad Announces Retirement of Dato' Abdullah Thalith Bin Md Thani as Independent and Non Executive Member of Audit Committee, Effective 23 May 2024 CI
Apr. 23 Amway Holdings Berhad Announces Retirement of Dato' Abdullah Thalith Bin Md Thani as Independent and Non Executive Director, Effective 23 May 2024 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The company is one of the best yield companies with high dividend expectations.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AMWAY (MALAYSIA) HOLDINGS Stock Amway (Malaysia) Holdings
+22.96% 249M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.43% 567B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.40% 234B
B+
NOVARTIS AG Stock Novartis AG
+4.84% 199B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 196B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. AMWAY Stock
  4. Ratings Amway (Malaysia) Holdings